Abstract:2059 Background: Our previous study showed A2B5+ glioma stem-like cell lysate-loaded DC vaccine (GSC-DCV) extended survival in recurrent GBM. Additionally, our earlier research indicates that A2B5+ GSCs, enriched with tumor-specific antigens like URGCP, have the potential to activate CD8+ T cells via dendritic cell antigen presentation. Recent research on recurrent GBM suggest aPD-1 mAb neoadjuvant therapy further extends survival. This study is intended to assess the safety and efficacy of this combined therapeutic approach. Methods: Patients with recurrent GBM (IDH1/2 -) post-radiotherapy and chemotherapy were enrolled. All patients received aPD-1 mAbs before surgery. Post-surgery, patients were randomly assigned to the monotherapy arm (aPD-1 mAbs and placebo) or combination therapy arm (aPD-1 mAbs and GSC-DCV), with treatments given every 3-6 weeks until disease progression or intolerable toxicity. The primary endpoint was OS, and secondary endpoints included PFS and trAEs. Results: A total of 21 patients were randomly assigned to the monotherapy (n=11) and combination therapy (n=10) arms. Patient characteristics were well-balanced. The monotherapy arm had a median OS of 8.2 months, while the combination arm showed a significantly longer OS of 22.7 months (HR, 0.2774; 95% CI, 0.0828 to 0.9291, P=0.0376). Multivariate Cox model analysis confirmed the independent prognostic impact of the combination therapy on patients with recurrent GBM (HR, 9.911; 95% CI, 1.520 to 64.623; P=0.016). There was no statistically significant difference in PFS between the two arms. Notably, patients in the combination group experienced a substantial improvement in post-progression survival (PPS) compared to the monotherapy group (7.8 m vs. 1.4 m; P=0.0266). The long survival benefit observed in the combination group was associated with continuous treatment, as cessation led to short-term tumor progression. Subgroup analysis based on tumor burden revealed that the combination therapy was significantly more effective in the low tumor burden cohort (mOS: 23.2 vs. 9.6 months; P=0.0162). No significant difference was observed in the monotherapy group between the two cohorts. High URGCP expression was significantly positively associated with OS in patients undergoing combination therapy (R2=0.8608, P=0.0061). Grade 1-2 trAEs were reported in 27.3% of patients in the monotherapy arm and 50.0% in the combination therapy arm. No grade 3 or higher trAEs occurred. Conclusions: The combination therapy has proven to be safe and well-tolerated. Although there was no significant improvement in PFS, patients achieved a sufficiently long OS benefit compared to the monotherapy arm. Notably, the combination therapy was particularly effective in patients with a low tumor burden through long-term, multi-course treatment. Clinical trial information: NCT04888611 .

Nonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination

Results from the first step of a phase II study of vaccination with autologous dendritic cells loaded with autologous tumour homogenate in glioblastoma.

The clinical utility of autologous tumor lysate‐loaded dendritic cell vaccination for patients with glioma: A systematic review and meta‐analysis

First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax)

Phase Ⅰ Study of Dendritic Cells Pulsed with Tumor Stem - Like Cells Associated Antigens Against Malignant Glioma in Recurrent Patients

Experimental Study of Treatment ofIntracranial G422 Glioblastoma with Bone Marrow-derived Dendritic Cells Vaccine

Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial

Immunotherapy of Intracranial G422 Glioblastoma with Dendritic Cells Pulsed with Tumor Extract or RNA

PL02.3.A Survival and T-cell tumor reactivity in patients treated with nivolumab and bevacizumab for recurrent glioblastoma in the clinical trial CA209-9UP

Dendritic cell vaccines for glioblastoma fail to complete clinical translation: Bottlenecks and potential countermeasures

Dendritic cell vaccine for glioblastoma: an updated meta-analysis and trial sequential analysis

TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial

CTIM-07. PHASE IIB RANDOMIZED, BLINDED, CONTROLLED TRIAL EVALUATING NEOADJUVANT PD-1 BLOCKADE COMBINED WITH A2B5+ GLIOMA STEM-LIKE CELL LYSATE-LOADED DCV IN RECURRENT GLIOBLASTOMA (IDH1/2 -)- TRAIL IN PROGRESS

Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma

First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity

Phase IIb Randomized, Blinded, Controlled Trial Evaluating Neoadjuvant PD-1 Blockade Combined with A2B5+ Glioma Stem-Like Cell Lysate-Loaded DC Vaccine in Recurrent Glioblastoma (IDH1/2 -).

Actively personalized vaccination trial for newly diagnosed glioblastoma

Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma

Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma

Glioblastoma vaccine tumor therapy research progress

1244 Immunotherapy With Autological Dendritic Cells in the Structure of Complex Treatment of Gliomas